BriaCell Provides Clinical Update on Ongoing Study of BriaVax

BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) provided an update on their open-label Phase I/IIa clinical trial evaluating the safety and efficacy of BriaVax treating advanced breast cancer.
As quoted in the press release:

“Our third patient has enrolled in the study, and we continue to see good progress in our clinical program. We continue to receive a high level of interest from patients with advanced breast cancer for this new treatment option. We remain optimistic regarding the prospects of this exciting trial, and are pleased that we remain on track to complete the enrollment of the first 10 patients by the end of Sept 2017. Interim data in these patients should be available in 1Q2018. These patients have widely metastatic breast cancer and have failed prior treatments,” stated Dr. Bill Williams, President & CEO of BriaCell.
“We are evaluating the efficacy profile of BriaVax^™ in addition to its safety profile. Furthermore, we will be assessing specimens from these patients using biomarkers to design BriaDx™, a diagnostic test to allow us to select the patients for which the vaccine will work at its best. We expect this innovative approach to be highly effective for the treatment of advanced breast cancer patients who have failed previous treatments, and have little to no therapeutic options for this deadly disease,” stated Dr. Williams.

Click here to read the full press release.

Source: www.marketwired.com